Sarepta Therapeutics CEO Doug Ingram is retiring after a tumultuous decade.[1] He has served as president, CEO and board member since 2017 and as CEO and board member since July 2025.[1] During his tenure, Sarepta's value increased to $15 billion and then declined.[1] In 2024, he aggressively sought the broadest possible approval of Elevidys gene therapy for Duchenne muscular dystrophy, including older boys and teenagers without walking, despite a lack of conclusive clinical data on safety and efficacy.[2] There was a patient death related to the limb-girdle muscular dystrophy program that the company did not consider a critical event and did not immediately report.[3] At the time, Sarepta announced a restructuring, laying off 36 percent of its workforce and halting two limb-girdle programs, including SRP-9004.[3] The company's shares fell nearly 36 percent to $14.07.[3] During Ingram's tenure from June 26, 2017 to December 23, 2025, there was repeated dilution of stock to shareholders.[4]